Clinical Trials in Detroit

Showing 16101-16120 of 19,719 trials

A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

NCT01963715

This is a Phase 1, first-in-human study to determine the recommended dose of IMGN289 in adult patients with advanced EGFR-positive tumors.

EGFR Positive Solid Tumors

ImmunoGen, Inc.20 participantsStarted Oct 2013

Los Angeles, California, United States • Baltimore, Maryland, United States • Boston, Massachusetts, United States +1 more locations

COMPLETEDPhase 3< 1 mile

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

NCT00085709

RATIONALE: Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different ways to stop cancer cells from dividing so they stop growing and die. Monoclonal antibodies, such as gemtuzumab ozogamicin, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with gemtuzumab ozogamicin may kill more cancer cells. It is not yet known whether induction therapy using cytarabine and daunorubicin is more effective with or without gemtuzumab ozogamicin or whether postconsolidation therapy using gemtuzumab ozogamicin is more effective than no additional therapy in treating de novo (first occurrence) acute myeloid leukemia. PURPOSE: This randomized phase III trial is comparing two different regimens of chemotherapy and monoclonal antibody therapy to see how well they work in treating patients with previously untreated de novo acute myeloid leukemia.

Leukemia

SWOG Cancer Research Network637 participantsStarted Jul 2004

Anchorage, Alaska, United States • Fort Smith, Arkansas, United States • Little Rock, Arkansas, United States +276 more locations

A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

Find Trials by Condition in Detroit

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

Test of a Web-based Intervention to Promote Hearing Protector Use

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders

Eplerenone in Hemodialysis Trial

Remote Ischemic Preconditioning in Cardiac Surgery Trial

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions

The Financial Impact of Allogeneic Stem Cell Transplantation on Patient and Family

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

AXIOS Stent With Electrocautery Enhanced Delivery System

Burn Outcomes in Young Adult Burn Survivors

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder